Prelude Therapeutics
PRLD
75 hedge funds and large institutions have $438M invested in Prelude Therapeutics in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 27 increasing their positions, 14 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
84% more call options, than puts
Call options by funds: $68K | Put options by funds: $37K
23% more funds holding
Funds holding: 61 → 75 (+14)
2.7% less ownership
Funds ownership: 100.92% → 98.22% (-2.7%)
61% less capital invested
Capital invested by funds: $1.12B → $438M (-$686M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.56M |
| 2 |
Two Sigma Investments
New York
|
+$4.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$4.36M |
| 4 |
BlackRock
New York
|
+$2.77M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.2M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$10.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.94M |
PRLD Hedge Fund Activity: Q4 2021 in Review
75 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2021, worth a combined $438M — down 61% from $1.12B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new PRLD positions and 12 closed out — a net gain of 14 holders — while 27 added to existing stakes and 14 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Fidelity Investments, cutting an estimated $18.2M.
- 75 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2021, up from 61 in Q3 2021.
- Funds reported $438M of Prelude Therapeutics stock for Q4 2021, down 61% quarter-over-quarter.
- 26 funds opened new Prelude Therapeutics positions in Q4 2021 and 12 closed out, a net change of +14 holders.
- The largest Prelude Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $6.56M added.
- The largest Prelude Therapeutics seller in Q4 2021 was Fidelity Investments, an estimated $18.2M sold.
Based on aggregated 13F filings for Q4 2021.